Global Transthyretin Amyloidosis Drug Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Transthyretin Amyloidosis Drug market size was valued at US$ 5985 million in 2024 and is forecast to a readjusted size of USD 9764 million by 2031 with a CAGR of 7.3% during review period.

Transthyretin amyloidosis is a slowly progressive disease in which abnormal deposits of a protein called amyloid occur in the body"s organs and tissues of the person. It is a progressive and fatal rare disease that can destroy nerve cells. It is often considered difficult to recognize and diagnose properly, and treatment is generally critical. However, the most common symptoms include heart failure, chronic diarrhea, weight loss, dry mouth, constipation, carpal tunnel syndrome, impaired kidney function, and floaters.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report is a detailed and comprehensive analysis for global Transthyretin Amyloidosis Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Transthyretin Amyloidosis Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Transthyretin Amyloidosis Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Transthyretin Amyloidosis Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031

Global Transthyretin Amyloidosis Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Transthyretin Amyloidosis Drug

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Transthyretin Amyloidosis Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc, AstraZeneca, Prothena Corporation plc, Ionis Pharmaceuticals, BELLUS Health Inc, Alnylam Pharmaceuticals, Inc, Eidos Therapeutics, Inc, SOM BIOTECH, Abbvie, Inc, Bausch Health Companies Inc, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Transthyretin Amyloidosis Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Tafamidis

Patisiran

Inotersen

Other

Market segment by Application

Hereditary Transthyretin Amyloidosis

Wild Transthyretin Amyloidosis

Major players covered

Pfizer Inc

AstraZeneca

Prothena Corporation plc

Ionis Pharmaceuticals

BELLUS Health Inc

Alnylam Pharmaceuticals, Inc

Eidos Therapeutics, Inc

SOM BIOTECH

Abbvie, Inc

Bausch Health Companies Inc

Bristol Myers Squibb Company

GSK Plc

Merck KGaA

Sanofi

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Transthyretin Amyloidosis Drug product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Transthyretin Amyloidosis Drug, with price, sales quantity, revenue, and global market share of Transthyretin Amyloidosis Drug from 2020 to 2025.

Chapter 3, the Transthyretin Amyloidosis Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Transthyretin Amyloidosis Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Transthyretin Amyloidosis Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Transthyretin Amyloidosis Drug.

Chapter 14 and 15, to describe Transthyretin Amyloidosis Drug sales channel, distributors, customers, research findings and conclusion.